Document is current
Any future updates will be listed below
-
Authors
Schöpf, Julia
Uhrig, Sebastian
Heilig, Christoph E. https://orcid.org/0000-0001-8869-1421
Lee, Kwang-Seok https://orcid.org/0000-0001-7682-5736
Walther, Tatjana
Carazzato, Alexander https://orcid.org/0009-0000-4353-0560
Dobberkau, Anna Maria
Weichenhan, Dieter
Plass, Christoph
Hartmann, Mark https://orcid.org/0000-0002-4072-4658
Diwan, Gaurav D.
Carrero, Zunamys I. https://orcid.org/0000-0001-8501-1566
Ball, Claudia R.
Hohl, Tobias https://orcid.org/0000-0002-2229-4391
Kindler, Thomas
Rudolph-Hähnel, Patricia
Helm, Dominic https://orcid.org/0000-0001-9321-2069
Schneider, Martin
Nilsson, Anna
Øra, Ingrid https://orcid.org/0000-0002-3931-4125
Imle, Roland https://orcid.org/0000-0001-9564-6952
Banito, Ana https://orcid.org/0000-0003-2188-0003
Russell, Robert B. https://orcid.org/0000-0002-1905-4717
Jones, Barbara C.
Lipka, Daniel B. https://orcid.org/0000-0001-5081-7869
Glimm, Hanno https://orcid.org/0000-0003-4104-1135
Hübschmann, Daniel https://orcid.org/0000-0002-6041-7049
Hartmann, Wolfgang https://orcid.org/0000-0002-7609-5021
Fröhling, Stefan https://orcid.org/0000-0001-7907-4595
Scholl, Claudia https://orcid.org/0000-0001-6768-322X
- License Information
-
More Information
Article History
Received: 23 March 2023
Accepted: 11 December 2023
First Online: 2 January 2024
Competing interests
: The authors declare the following competing interests: C.E.H. has received research funding from AstraZeneca, Pfizer, PharmaMar, and Roche. I.Ø. has received funding from AstraZeneca and Pfizer. D.B.L. has received honoraria from Illumina and is an employee of Infectopharm. S.F. has had a consulting or advisory role and received honoraria, research funding, and/or travel/accommodation expenses funding from the following for-profit companies: Amgen, AstraZeneca, Bayer, Eli Lilly, Pfizer, PharmaMar, and Roche. The other authors declare no competing interests.
